VYNE Therapeutics Inc. Common Stock (VYNE)
VYNE Therapeutics Inc. is a biopharmaceutical company focused on developing innovative, prescription-based therapies for dermatologic conditions. Founded with the goal of addressing underserved skin diseases, VYNE leverages proprietary formulations and technologies to create targeted treatments. The company’s portfolio includes products aimed at conditions such as atopic dermatitis and other inflammatory skin disorders.
Company News
Over 18 pharmaceutical companies are developing targeted therapies for vitiligo, with promising pipeline drugs showing potential to transform treatment options beyond conventional approaches like corticosteroids and phototherapy.
Across the recent three months, 4 analysts have shared their insights on VYNE Therapeutics (NASDAQ:VYNE), expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bulli...
VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of 37.50% and 2%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Penny stocks to buy according to analysts. The post 4 Penny Stocks To Buy According To Analysts, Targets Up To 1,560% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
VYNE earnings call for the period ending June 30, 2021.